EU CHMP snubs Biogen and Eisai’s Alzheimer’s therapy Leqembi
The European agency said that Leqembi’s efficacy was “not large enough” to outweigh its safety risks.
The European agency said that Leqembi’s efficacy was “not large enough” to outweigh its safety risks.
What's Your Reaction?
